Yi Zhang

机构：Biothera (United States), Hologic (United States) · ORCID：0009-0004-6107-2232

发表论文 16 篇 · 总被引 85 次 · h-index 3

代表论文

• Occurrence and distribution of per- and polyfluoroalkyl substances (PFASs) in human livers with liver cancer (2021 · Environmental Research · 被引 69)
• Comparative performance of Breast Cancer Index (BCIN+) and CTS5 in hormone receptor-positive (HR+) lymph node-positive (N+) breast cancer patients with one to three positive nodes (N1). (2019 · Journal of Clinical Oncology · 被引 5)
• Breast cancer index (BCI) predicts benefit of two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the ideal trial. (2020 · Journal of Clinical Oncology · 被引 4)
• Abstract GS1-06: Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial (2023 · Cancer Research · 被引 3)
• Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index (2025 · JAMA Network Open · 被引 2)
• Genomic stratification with BCI of ER+ early breast cancer patients with limited long-term risk of breast cancer death. (2018 · Journal of Clinical Oncology · 被引 1)